指南与共识泌尿生殖技术与安全PETCT

PSMA PET/CT肿瘤体积评估对177Lu-PSMA放射性配体治疗后生存的预后价值:基于PSMA PET/CT共识声明与RECIP 1.0

Prognostic Value of Tumor Volume Assessment on PSMA PET After 177Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0.
指南 / 共识 · J Nucl Med · 2022-10-27

本研究回顾性纳入70例转移性去势抵抗性前列腺癌患者,分别接受68Ga-PSMA-11或18F-PSMA-1007 PET/CT监测,评估基于50%病灶SUVmax阈值的半自动全身体积(PSMATV50)及其变化(ΔPSMATV50)对总生存(OS)的预测价值。结果显示基线PSMATV50和ΔPSMATV50在两种示踪剂中均与OS显著相关,且将ΔPSMATV50整合入PSMA PET/CT共识声明和RECIP 1.0后,两种分类系统对OS均表现出高判别力(一致性概率估计分别为0.73和0.74)。

要点

  • 基线PSMATV50和ΔPSMATV50在68Ga-PSMA-11和18F-PSMA-1007中均与OS独立相关。
  • ΔPSMATV50整合入PSMA PET/CT共识声明和RECIP 1.0后,预后判别力高且相近。
  • 半自动50% SUVmax阈值法测量全身体积技术上可行,可重复用于疗效评估。

局限性

  • 回顾性研究设计。
  • 未报告多中心外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Quantitative evaluation of prostate-specific membrane antigen (PSMA)-targeting PET/CT remains challenging but is urgently needed for the use of standardized PET-based response criteria, such as the PSMA PET/CT consensus statement or Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0). A recent study evaluated the prognostic value of whole-body tumor volume using a semiautomatic method relying on a 50% threshold of lesion SUVmax (PSMATV50). In the present study, we analyzed the suitability of this approach comparing 18F-PSMA-1007 with 68Ga-PSMA-11 PET/CT scans and the potential of PSMATV50 for the prediction of overall survival (OS) in patients before 177Lu-PSMA radioligand therapy (RLT). Moreover, PSMATV50 was integrated into the PSMA PET/CT consensus statement as well as RECIP 1.0, and the prognostic value of these response classification systems was compared. Methods: This retrospective study included 70 patients with metastatic castration-resistant prostate cancer undergoing PSMA RLT. Thirty-three patients were monitored by 68Ga-PSMA-11 PET/CT, and 37 patients by 18F-PSMA-1007 PET/CT. PET/CT scans before (baseline) and at the end of PSMA RLT after 2-4 cycles (follow-up) were separately analyzed by 2 readers. PSMATV50 at baseline and its change at the time of follow-up (ΔPSMATV50, expressed as a ratio) were correlated with OS using Cox proportional-hazards regression. The results of both subgroups were compared. The integration of ΔPSMATV50 in existing response classification systems was evaluated. To assess and compare the discriminatory strength of these classification systems, Gönen and Heller concordance probability estimates were calculated. Results: PSMATV50 determination was technically feasible in all examinations. A higher PSMATV50 at baseline and a higher ΔPSMATV50 were strongly associated with a shorter OS for both 68Ga-PSMA-11 (PSMATV50: hazard ratio [HR] of 1.29 [95% CI, 1.05-1.55], P = 0.009; ΔPSMATV50: HR of 1.83 [95% CI, 1.08-3.09], P = 0.024) and 18F-PSMA-1007 (PSMATV50: HR of 1.84 [95% CI, 1.13-2.99], P = 0.014; ΔPSMATV50: HR of 1.23 [95% CI, 1.04-1.51], P = 0.03). Response assessment provided high discriminatory power for OS for the PSMA PET/CT consensus statement (concordance probability estimate, 0.73) as well as RECIP 1.0 (concordance probability estimate, 0.74). Conclusion: PSMATV50 and ΔPSMATV50 proved to be predictive of OS not only for 68Ga-PSMA-11 but also for 18F-PSMA-1007 PET/CT scans. Subsequent integration of ΔPSMATV50 into the PSMA PET/CT consensus statement and RECIP 1.0 provided equally high prognostic value for both classification systems.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kind, Eder, Jilg, et al. Prognostic Value of Tumor Volume Assessment on PSMA PET After 177Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0. J Nucl Med. 2022. PMID: 36302658. doi:10.2967/jnumed.122.264489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。